Endocrine Abstracts

Introduction: There have been described that about 50% of women diagnosed with PCO-S, present lipid metabolism disorders, insulin resistance and incorrect blood pressure. They suffer not only from fertility disorders, but also present a risk of metabolic complications such as: obesity, type 2 diabetes and hypertension, which increase diet-related cancers and cardiovascular risk.

Aim: To explore if serum omentin concentration could be an indicator of cardiovascular risk in PCO-S, lipid panel, SBP, DBP and QUICKI values, also predisposing CVD factors were assesed.

Material and Methods: 33 women, aged 18-39, with PCO-S were included in the study. The patients were hospitalized in Endocrinology City Hospital in Piekary in 2015-2019. The predisposing CVD factors were: BP different from <120/80 mmHg, TC > 190 mg/dl, LDL > 135 mg/dl, HDL < 50 mg/dl, TGC > 150 mg/dl, HOMA-IR > 1.5, glucose > 100 mg/dl, BMI > 24.9, smoking and reduced physical activity and assigned 1 point for every existed factor. Anthropometric measurements were conducted and blood parameters from the medical patients records were taken. To determine the serum omentin concentration ELISA method was used. Statistically significant value P < 0.05 was assumed.

Results: The average serum omentin concentration in examined women was 274 ng/ml (± 78), TC concentration was 193 mg/dl (± 45), BP value 121/76 mmHg (± 12) and QUICKI value was 0.3 (± 03.05). Statistically significant negative correlation between serum omentin concentration and SBP and DBP was shown (P = 0, 03; P = 0,002). As the concentration of omentin increased, an increase in QUICKI value was observed (P = 0.001). Negative correlation was observed between serum omentin concentration and predisposing CVD factors (P = 0.008). There were no correlation between serum omentin concentration and lipid panel values.

Conclusion: Serum omentin concentration could be an useful tool to demonstrate the risk of CVD in women with PCO-S. Further studies in a larger group are required to confirm the CVD risk diagnostic value of omentin.